Pure Global AI
NCT06322108Not yet recruiting

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Immune Oncology Research InstitutePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Botensilimab + Balstilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Immune Oncology Research Institute
Location
Yerevan, Armenia
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Apr 01, 2030
Enrollment
45 participants
Primary outcome

12-Month Progression-Free Survival (PFS)

Summary

The goal of this study is to see if the combination of immunotherapy agents botensilimab and
 balstilimab is safe and effective in participants with metastatic non-small cell lung cancer
 (NSCLC) as a first-line treatment.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06322108
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06322108 through Pure Global AI's free database. This Phase 2 trial is sponsored by Immune Oncology Research Institute and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.